Journal of gastroenterology and hepatology
-
J. Gastroenterol. Hepatol. · Aug 2019
Meta AnalysisVonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
Gastroesophageal reflux disease (GERD) is a common disease caused by reflux of gastric contents to the esophagus. Proton-pump inhibitors (PPIs) are recommended as a first-line therapy to treat GERD. Recently, a new potassium-competitive acid blocker, vonoprazan, was launched in Japan. We aimed to evaluate the comparative efficacy of vonoprazan and other PPIs in healing GERD. ⋯ This analysis shows that the GERD healing effect of vonoprazan is higher than that of rabeprazole (20 mg) but not higher than other PPIs. Subgroup analysis indicated that vonoprazan is more effective than most PPIs for patients with severe erosive esophagitis.
-
J. Gastroenterol. Hepatol. · Aug 2019
Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
The recommendation in regard to screening for non-alcoholic fatty liver disease (NAFLD) among type 2 diabetes mellitus (T2DM) patients differs in major guidelines. The aim of this paper was to study the prevalence of NALFD and advanced fibrosis among T2DM patients. ⋯ The prevalence of NAFLD and advanced fibrosis based on transient elastography is high among T2DM patients.
-
J. Gastroenterol. Hepatol. · Jul 2019
Comparative StudyRegional variations in the use of biologics and immunomodulators among Korean patients with inflammatory bowel diseases.
Variation in medical care can be an obstacle to improving quality and outcome of treatment. We conducted a nationwide, population-based study to identify regional variations in medication prescription rates in Korean patients with inflammatory bowel diseases (IBDs). ⋯ Regional variation exists in medication prescription rates within a single city as well as nationwide, suggesting that standardization of IBD treatment is necessary in Korea.
-
J. Gastroenterol. Hepatol. · May 2019
Meta AnalysisPeripherally acting μ-opioid antagonist for the treatment of opioid-induced constipation: Systematic review and meta-analysis.
Opioid-induced constipation (OIC) is a frequent adverse event (AE) that impairs patients' quality of life (QOL). Peripherally acting μ-opioid receptor antagonists (PAMORAs) have been recognized as a treatment option for OIC, but the effect consistent across the studies has not been evaluated. ⋯ Peripherally acting μ-opioid receptor antagonist has been shown to be effective and durable for patients with OIC and is the only drug with confirmed evidence in meta-analysis. The possibility of publication bias was the limitation of this study.